Cortechs.ai | Cortechs.ai and Olea Medical partner to offer NeuroQuant<sup>®</sup> to more customers

Cortechs.ai and Olea Medical partner to offer NeuroQuant® to more customers

 Cortechs.ai announces collaboration with Olea Medical for quantifying brain volume loss using NeuroQuant.

(SAN DIEGO) May 23, 2016 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, and Olea Medical®, a provider of advanced MR and CT imaging post-processing and visualization, are pleased to announce a partnership agreement to offer NeuroQuant® in Olea Sphere®, Olea Medical’s suite of innovative imaging applications.

The partnership will enrich physicians’ resources for accessing and quantifying neurodegeneration. NeuroQuant provides automatic, accurate and consistent measurements of brain structures through 3D T1 MRI images, allowing neurologists and radiologists to easily review, assess, quantify and monitor brain volume loss and changes over time, as compared to normative values.

NeuroQuant, the first FDA cleared, CE marked and Health Canada licensed software for measuring brain volumes and quantifying brain atrophy, is used in the assessment of neurodegeneration, such as Alzheimer’s disease, epilepsy, multiple sclerosis, as well as, brain volume changes caused by brain trauma.

Olea Sphere is an image processing software package intended for picture archive, post-processing and communication. It helps standardize both viewing and analysis capabilities of functional and dynamic imaging datasets acquired with MRI and CT across vendors. It features innovative image viewing, analysis and processing of most complex MR sequences as well as longitudinal analysis of multiple time points. Olea Sphere® is compliant with the DICOM standard and Windows® or Linux® operating systems. Olea Sphere® runs on any standard off-the-shelf workstation or it can be used through thin deployment.

“We’re very excited to partner with Olea Medical to provide our objective quantitative imaging solutions to neurologists and radiologists worldwide,” said Guri Stark, Cortechs.ai’ CEO.  “We believe this collaboration will significantly benefit clinicians using Olea Sphere in their assessment of neurodegeneration and provide a beneficial insights for many brain disorders.”

“We are always looking to provide our customers with enhanced and expanded imaging capabilities,” said Fayçal Djeridane, CEO, Olea Medical. “By adding NeuroQuant’s proven and validated solutions to our Olea Sphere offering, healthcare providers worldwide have access to innovative automated brain volume imaging technology, allowing them to deliver better patient care.”

For more information about using NeuroQuant in Olea Sphere, please visit Cortechs.ai at Booth 317 or Olea Medial at Booth 318 during the American Society of Neuroradiology (ASNR) 2016 Annual Meeting (May 23-25, Washington, DC).

About Cortechs.ai
Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of MRI images of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit cortechs.ai for further information.

About Olea Medical
Olea Medical®, a provider of advanced MR and CT imaging post-processing, designs and markets a suite of innovative medical imaging applications, Olea Sphere®, significantly improving diagnostic process and follow-up assessment. The company has established a strong credibility, through the domestication of cutting-edge technology, and partnerships with leading institutions worldwide. With proprietary Bayesian algorithms and optimization methods applied to medical imaging, today Olea Medical® is the recognized leader in standardized, vendor-neutral, advanced MR quantitative and qualitative image post-processing. Covering both morphologic and functional imaging, Olea Medical® post-processing solutions bring complex mathematics into clinical practice for easy access to accurate and robust biomarkers for enhanced diagnostic confidence and response-to-treatment assessment. More information at www.olea-medical.com.

###

Media Contact
Travis Foegler
Phone: +1 (619) 450-9094
Email: Tfoegler@cortechs.ai

More Resources

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

02/19/2026

How Cortechs.ai Protects ePHI: HIPAA‑Aligned Controls—and Beyond

Cortechs.ai’s HIPAA-aligned, defense-in-depth security safeguards ePHI across AI workflows—exceeding baseline compliance standards.
Scroll to Top